August 16, 2025

New Comorbidity Index Associated with Survival After Chimeric Antigen Receptor T Cell Therapy for Large B-Cell Lymphoma.

View Full Paper

Ask AI

Bookmark

Authors

UGUri GreenbaumBen-Gurion University of the Negev HHHamza HashmiMemorial Sloan Kettering Cancer Center MEMahmoud ElsawyDalhousie University

Discussion

Member takes

Implication

Observational analysis found a novel comorbidity index predicts overall survival in patients with large B-cell lymphoma, indicating its utility in treatment decisions.

Key Points

Higher comorbidity index scores were associated with increased mortality, affecting overall survival rates.
Patients with higher CT-CI scores showed a hazard ratio of 2.55, indicating a significantly worse prognosis.
The study evaluated patients aged 18 or older receiving CAR-T therapy from the CIBMTR registry, focusing on survival outcomes.
The findings suggest that comorbidities can inform clinical decision-making without restricting access to CAR-T therapy.

Cite This Study

Greenbaum et al. (2025) studied this question.

synapsesocial.com/papers/68a368840a429f797332da2a https://doi.org/10.1182/bloodadvances.2024015599

View Full Paper

Ask AI

Bookmark

Implication

Observational analysis found a novel comorbidity index predicts overall survival in patients with large B-cell lymphoma, indicating its utility in treatment decisions.

New Comorbidity Index Associated with Survival After Chimeric Antigen Receptor T Cell Therapy for Large B-Cell Lymphoma.

Discussion

Member takes

Implication

Key Points

Cite This Study

New Comorbidity Index Associated with Survival After Chimeric Antigen Receptor T Cell Therapy for Large B-Cell Lymphoma.

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider